http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yuto Shoji,Hirokazu Madokoro,Stephanie Nix,Kazuki Saruta,Takashi K. Saito,Kazuhito Sato 제어로봇시스템학회 2022 제어로봇시스템학회 국제학술대회 논문집 Vol.2022 No.11
The number of accidents involving pedestrians and bicyclists has been reported to be about 1.8 times higher on narrow roads than on arterial roads in Japan. We consider investigating the circumstances under which accidents occur on narrow roads to be an important research task. Statistics from the Tokyo Metropolitan Police Department indicate that the number of traffic accident fatalities in winter is relatively high. We used a Driving Simulator (DS) in order to safely perform sensing on roads that replicate a local city in a heavy snowfall region. Brain activity during driving was measured using a portable functional Near-Infrared Spectroscopy (fNIRS) device. We used a machine-learning algorithm for analyzing time-series datasets to demonstrate differences in brain activity across driving events. We classified subjects into four groups based on the results of questionnaires that assessed their driving characteristics. Experimentally obtained results demonstrated that Root Mean Squared Error (RMSE) changes that represent increased brain activity were greater in winter than in summer for each event. We infer that the winter events had a larger impact on the drivers.
Sasaki, Yusuke,Hamaguchi, Tetsuya,Yamada, Yasuhide,Takahashi, Naoki,Shoji, Hirokazu,Honma, Yoshitaka,Iwasa, Satoru,Okita, Natsuko,Takashima, Atsuo,Kato, Ken,Nagai, Yushi,Taniguchi, Hirokazu,Boku, Nari Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.2
Background: It is well known that peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is associated with a poor prognosis. However, data on the prognostic significance of modern chemotherapy containing bevacizumab, cetuximab or panitumumab are not available. Materials and Methods: This retrospective review concerned 526 patients with metastatic CRC who were classified into two groups according to the presence or absence of PC, and were treated with systemic chemotherapy, with or without bevacizumab or anti-EGFR antibodies. The genetic background, in particular KRAS, BRAF, and PIK3CA gene mutations, and overall survival (OS) were compared between the two groups. Results: The median OS values were 23.3 and 29.1 months for PC and non-PC patients, respectively (hazard ratio [HR]=1.20; p=0.17). Among all patients, tumor location, number of metastatic sites and BRAF mutation status were significant prognostic factors, whereas the presence of PC was not. In the PC group, chemotherapy with bevacizumab resulted in a significantly longer OS than forchemotherapy without bevacizumab (HR=0.38, p<0.01), but this was not the case in the non-PC group (HR=0.80, p=0.10). Furthermore, the incidence of the BRAF V600E mutation was significantly higher in PC than in non-PC patients (27.7% versus 7.3%, p<0.01). BRAF mutations displayed a strong correlation with shorter OS in non-PC (HR=2.26), but not PC patients (HR=1.04). Conclusions: Systemic chemotherapy, especially when combined with bevacizumab, improved survival in patients with PC from CRC as well as non-PC patients. While BRAF mutation demonstrated a high frequency in PC patients, but it was not associated with prognosis.
Masayuki Ohashi,Toru Hirano,Kei Watanabe,Kazuhiro Hasegawa,Takui Ito,Keiichi Katsumi,Hirokazu Shoji,Tatsuki Mizouchi,Ikuko Takahashi,Takao Homma,Naoto Endo 대한척추외과학회 2019 Asian Spine Journal Vol.13 No.2
Study Design: Retrospective case series. Purpose: To investigate the oncological outcomes, including distant relapse, after en bloc spondylectomy (EBS) for spinal metastases in patients with a minimum of 2-year follow-up. Overview of Literature: Although EBS has been reported to be locally curative and extend survival in select patients with spinal metastases, detailed reports regarding the control of distant relapse after EBS are lacking. Methods: We conducted a retrospective review of 18 consecutive patients (median age at EBS, 62 years; range, 40–77 years) who underwent EBS for spinal metastases between 1991 and 2015. The primary cancer sites included the kidney (n=7), thyroid (n=4), liver (n=3), and other locations (n=4). Survival rates were estimated using the Kaplan–Meier method, and groups were compared using the log-rank method. Results: The median operative time and intraoperative blood loss were 767.5 minutes and 2,375 g, respectively. Twelve patients (66.7%) experienced perioperative complications. Five patients (27.8%) experienced local recurrence of the tumor at a median of 12.5 months after EBS, four of which had a positive resection margin status. Thirteen patients (72.2%) experienced distant relapse at a median of 21 months after EBS. The estimated median survival period after distant relapse was 20 months (95% confidence interval, 0.71–39.29 months). No association was found between resection margin status and distant relapse. Overall, the 2-year, 5-year, and 10-year survival rates after EBS were 72.2%, 48.8%, and 27.1%, respectively. Importantly, the era in which EBS was performed did not impact the oncological outcomes. Conclusions: Our results suggest that EBS by itself, even if margin-free, cannot prevent further dissemination, which occurred in >70% of patients at a median of 21 months after EBS. These results should be considered and conveyed to patients for clinical decision-making.